Background: The von Hippel-Lindau (VHL) tumor suppressor gene and hypoxia-inducible factor-1a (HIF1A) play a pivotal role in renal carcinogenesis. This study was aimed to clarify the influence of VHL and HIF1A polymorphisms on renal cell cancer (RCC) susceptibility and survival.
introduction
Renal cell cancer (RCC) is the predominant form of malignancy of the kidney (>80%) and the 10th most common cause of cancer-related deaths among men [1, 2] . Although the rate of detection of RCC has increased with improved diagnostic techniques, it is estimated that 25% of patients have metastatic disease at the moment of diagnosis and 30% of the remaining surgically treated patients will develop metastases [3, 4] . After detecting these metastases, the 5-year survival rate generally is <10% [3] . However, prediction of RCC prognosis largely depends on the conventional prognostic factors such as pathologic tumor stage and grading. To accurately predict the cancer-related survival of RCC, other novel prognostic parameters including clinical, laboratory, and genetic variations may be needed. Recently, some studies showed that genetic polymorphisms of candidate genes were associated with susceptibility and/or prognosis in patients with RCC [5] [6] [7] [8] [9] .
In various types of tumors, including urologic malignancies, it has been reported that angiogenesis is closely associated with advanced disease status and poor prognosis. Hypoxia-inducible factor-1 (HIF-1) plays a key role in renal tumorigenesis through regulating genes that are involved in angiogenesis, erythropoiesis, cell adhesion, metastatic spread, apoptosis, and glucose metabolism [10] . HIF-1 is a heterodimeric transcription factor consisting of a and b subunits, of which HIF-1a is the oxygen-regulated factor that determines HIF-1 activity. The von Hippel-Lindau tumor suppressor protein (pVHL) is a key mediator of HIF-1a. Under normoxic conditions, HIF-1a is targeted for ubiquitin-mediated degradation by the proteasome, which is mediated by pVHL acting as a component of the E3 ubiquitin-protein ligase complex, which targets the minimal N-terminal transactivation domain (N-TAD) [11] . Under hypoxic conditions, degradation of HIF-1a is suppressed and then HIF-1a is rapidly accumulated in the cell. Inactivation of pVHL leading to constitutive activation of HIF-1a has been thought to play a central role in renal tumorigenesis.
Two single-nucleotide polymorphisms (SNPs) in HIF1A, which result in proline-to-serine (rs11549465) and alanine-tothreonine (rs11549467) amino acid substitutions, respectively, were found within the N-TAD of HIF-1a [12] . There have been several polymorphism studies of HIF1A for various cancer types in different populations [13] [14] [15] [16] , including RCC [17] . In head and neck squamous cell carcinoma, it was suggested that variants of these two polymorphisms significantly enhanced transcription activities compared with wild type and these polymorphic variants were associated with higher disease stage [14] . In bladder cancer and oral cancer, these polymorphic variants were suggested to associate with unfavorable prognosis [18, 19] . In colorectal cancer, these polymorphisms are an important factor for the development of ulcerative cancer [20] . These studies suggest that the HIF1A polymorphisms may have effects on tumor progression and prognosis. Although Ollerenshaw et al. [17] showed that these two polymorphic variants were significantly associated with increased risk for RCC, there is no study that investigates the influence of these HIF1A polymorphisms on the progression and prognosis of RCC.
Given the important role of von Hippel-Lindau (VHL)/HIF1a pathway in stimulating angiogenesis, prompting tumor cell proliferation, invasion, and metastasis, it is conceivable that polymorphic variations in VHL or HIF1A may have an effect on the risk or prognosis of RCC. To test this hypothesis, we selected four potentially functional SNPs in VHL and HIF1A based on previous reports [17] and HapMap data (http:// hapmap.ncbi.nlm.nih.gov/), of which rs11549465 and rs11549467 in HIF1A have been widely studied in various kinds of cancer, whereas rs2057482 in HIF1A and rs779805 in VHL have not been reported by previous studies regarding cancer risk or prognosis.
patients and methods

study population
Our study was approved by the Institutional Review Board of the Nanjing Medical University, Nanjing, China. In total, 620 patients and a group of 623 cancer-free controls were enrolled in the case-control study. All subjects in our study are ethnic Han Chinese coming from different families and have no blood relationship. All the patients were newly diagnosed and had histopathologically confirmed incident RCC without prior history of other cancers or previous chemotherapy or radiotherapy and were consecutively recruited into an ongoing study from May 2004 at The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [21] . Disease was classified according to the World Health Organization criteria and staged according to the American Joint Committee on Cancer (AJCC) TNM (tumor-node-metastasis) classification. Based on the TNM classification system promulgated by the AJCC, the disease stage was divided into localized (stage I and stage II) and advanced RCC (stage III and stage IV). The Fuhrman scale was used to assess tumor nuclear grade. The controls were recruited from healthy subjects who were seeking health care in the outpatient departments at the hospital and were frequency matched to the cases on sex and age (65 years). The cancer-free controls were genetically unrelated to the cases and had no individual history of cancer. Before recruitment, a standard questionnaire was administered through face-to-face interviews by trained interviewers to collect demographic data and related factors. Each patient donated 5 ml venous blood after providing a written informed consent. The response rate for both case and control subjects was >85%. For the survival analysis, a total of 365 RCC cases enrolled in our ongoing cohort study from May 2004 to October 2009 were used. The patients were followed up prospectively every 6 months from the time of enrollment by family contacts until death or last time of follow-up. Of these, 51 patients (14.0%) were excluded due to lack of adequate information for follow-up. Three patients (0.8%) who could not be genotyped (which may be due to low DNA quality) were also excluded from the study. The maximum follow-up time was 72 months (last follow-up in August 2010) and the median follow-up time was 25.1 months.
SNP selection
SNPs in VHL and HIF1A were selected based on previous reports [17] and HapMap data (http://hapmap.ncbi.nlm.nih.gov/). The potentially functional polymorphisms were identified according to the following criteria: (i) located in the 5# flanking regions, 5# untranslated region (UTR), 3# UTR, and coding regions with amino acid changes; (ii) minor allele frequency (MAF) > 5% in Chinese population; and (iii) associated with cancer risk or survival in previous studies. According to the criteria, three SNPs were identified in VHL (rs779803, rs779805, and rs1462742) and two SNPs in HIF1A (rs11549467 and rs2057482). However, these three SNPs in VHL were in complete linkage disequilibrium (r 2 = 1), thus only one SNP (rs779805 in 5# UTR) was selected for genotyping. We also selected another SNP (rs11549465 in exon12) in HIF1A, which was reported to associate with RCC susceptibility [17] , although the MAF was <5% in Chinese population. Finally, four SNPs were selected and genotyped (rs779805 in 5# UTR region of VHL and rs11549465 in exon12, rs11549467 in exon12, and rs2057482 in 3# UTR region of HIF1A).
DNA extraction and genotyping
Genomic DNA was extracted from the peripheral blood by proteinase K digestion and phenol-chloroform extraction. The genotyping of the four polymorphisms was carried out using predesigned TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA). The sequences of primer and probe for each SNP are available on request. According to the manufacturer's instructions, amplifications and analysis were carried out in the 384-well ABI 7900HT Real-Time PCR System (Applied Biosystems), using the SDS 2.3 software for allelic discrimination (Applied Biosystems). Controls were included in each plate to ensure accuracy of the genotyping. About 10% of the samples were randomly selected for repeated genotyping for confirmation, and the results were 100% concordant.
statistical analyses
SNP allele frequencies were tested against departure from Hardy-Weinberg equilibrium using a goodness-of-fit v 2 test before analysis. Differences in the distributions of demographic characteristics, selected variables, and frequencies of genotypes between cases and controls were evaluated using the Student's t-test (for continuous variables) or v 2 test (for categorical variables). The associations between polymorphisms and risk of RCC were estimated by computing odds ratios and 95% confidence intervals (CIs) from unconditional logistic regression analysis with the adjustment for possible confounders. Survival time was calculated from the date of RCC diagnosis to the date of death or last follow-up. The different survival times according to demographic characteristics, clinical features, and VHL/HIF1A polymorphisms were estimated by using the Kaplan-Meier method and compared by the log-rank test; P < 0.05 was considered statistically significant. Univariate or multivariate Cox regression analysis was done to determine predictive factors of RCC survival by estimating the crude hazard ratios (HRs), adjusted HRs, and their 95% CIs, with adjustment for possible confounders. All analyses were carried out with the software SAS 9.1.3 (SAS Institute, Cary, NC) with two-sided P values.
results
characteristics of RCC patients and controls
The frequency distributions of selected characteristics of the 620 cases and 623 controls are shown in Table 1 . There were no significant differences between the cases and controls with regards to age, sex, body mass index, drinking status, and packyears of smoking (all P > 0.05). However, there were more smokers, hypertension patients, and diabetics among the cases than among the controls (P = 0.048, P = 0.001, and P < 0.001, respectively). The majority of patients (83.6%) had the conventional clear-cell carcinoma. Eighteen patients (2.9%) had papillary carcinoma and others including chromophobe and unclassified RCC accounted for 6.4% and 7.1% of all the carcinoma, respectively. Of 620 patients, 26 (4.2%) patients developed lymph node metastasis and 35 (5.6%) patients developed distant metastasis. Approximately 44.8% of the patients have larger tumors (>4 cm). In addition, 63.6% of the patients were in stage I, whereas 18.6%, 6.8%, and 11.0% were found to have stage II, III, and IV diseases, respectively. The percent of nuclear grade from I to IV was 18.6%, 47.9%, 24.8%, and 8.7%, respectively.
genotype and allele frequencies of VHL and HIF1A polymorphisms in the RCC cases and controls
Allele frequencies and genotype distributions of VHL and HIF1A polymorphisms in patients and controls are shown in Table 2 . All observed genotype frequencies in both controls and patients conform to the Hardy-Weinberg equilibrium. No significant differences in genotype and allele frequencies of VHL or HIF1A polymorphisms were observed between RCC patients and controls (P = 0.966 for VHL rs779805; P = 0.939, 0.483, and 0.657 for HIF1A rs11549465, rs11549467, and rs2057482, respectively). It was reported that HIF1A rs11549465 polymorphism was significantly associated with type 2 diabetes [22, 23] . Since there were more diabetics among patients than controls in our study and this imbalance might influence the association of rs11549465 and RCC risk, we then analyzed the frequencies according to diabetes disease in both groups. However, no significant differences were observed between rs11549465 genotypes and diabetics in both groups (data not shown). Recently, synergistic effect between gene polymorphism of HIF1A rs11549467 and environmental risk factors, such as tobacco and alcohol consumptions, for development of hepatocellular cancer has been reported [24] . Since smoking is a risk factor for development of RCC, we also investigated influence of these four polymorphisms on RCC risk stratified by smoking. However, no positive results were observed (data not shown).
effects of VHL and HIF1A polymorphisms on clinicopathological characteristics of RCC patients
The associations of VHL and HIF1A polymorphisms with clinicopathological parameters of RCC are shown in Table 3 . The CT and CT+TT genotypes of rs2057482 were significantly less frequent in patients with lymph node metastasis than in those without (P = 0.026 and P = 0.022, respectively). In combined analysis, patients with ‡2 variant alleles of the four polymorphisms were significantly associated with less frequency in lymph node metastasis and associated with localized clinical stage (P = 0.032 and P = 0.041, respectively). There were no significant associations between the evaluated genotypes and primary tumor stage, distant metastasis, tumor size. or tumor grade.
effects of VHL and HIF1A polymorphisms on RCC survival
Cox regression analyses were used to access the associations between genotypes of the four SNPs in VHL or HIF1A and survival of patients with RCC. As shown in Table 4 , although we did not observe a significant association of each genotype of these four SNPs with survival of RCC, the variant genotypes of each polymorphism were associated with improved 5-year survival compared with the corresponding wild genotype. Since each of these four SNPs appeared to have a minor effect on RCC survival, we then combined them to evaluate their joint effect on the survival of RCC. As shown in Table 4 , for trichotomized groups, the number of variant alleles was associated with a significantly improved survival in a doseresponse manner. Compared with individuals with 0 variant alleles, individuals with 1 or ‡2 variant alleles had improved RCC survival (HR = 0.54, 95% CI 0.25-1.18 and HR = 0.27, 95% CI 0.08-0.99, respectively; log-rank P = 0.045), and the trend in survival associated with the number of variant alleles was statistically significant (log-rank test for trend P = 0.013).
Considering the deaths, the number of individuals with more than two variant alleles was small (only 3); in further analysis, we divided the patients into 0 variant alleles group and ‡1 variant alleles group. We found that individuals with ‡1 variant genotypes had a significantly improved survival compared with individuals with no variant alleles (log-rank P = 0.043, HR = 0.46; 95% CI 0.22-0.95). Kaplan-Meier curves were calculated for cancer-specific survival stratified according to the number of variant genotypes ( ‡1 versus 0 variant alleles; Figure 1C ).
Cox proportional hazard analysis for overall survival of RCC
We further did a univariate and multivariate Cox proportional hazard analysis for survival of RCC patients. As show in Table 5 and Figure 1 , in the univariate analysis, clinical stage, tumor grade, and the number of variant alleles ( ‡1 versus 0) were associated with RCC survival. In the multivariate analysis, the results suggested that clinical stage was the best prognostic factor for RCC survival followed by tumor grade (P < 0.0001, HR = 13.28; 95% CI 5.59-32.02 and P = 0.003, HR = 4.09; 95% CI 1.63-10.24, respectively) ( Table 5 ). Interestingly, variant alleles ( ‡1 versus 0) of the four polymorphisms in VHL and HIF1A were also an independent risk factor for RCC survival (P = 0.036, HR = 0.46; 95% CI 0.22-0.95).
discussion
In the present study, we investigated the associations between the VHL and HIF1A functional polymorphisms and RCC susceptibility, progression, and survival. Although no significant differences of genotype frequencies between cases and controls were observed, our results suggested that, in combined analysis, genetic variations in VHL/HIF1A were associated significantly with less frequent lymph node metastasis, lower clinical stage, and improved survival of RCC patients. To our knowledge, this is the first report of an association of VHL/HIF1A polymorphisms with progression and survival in patients with RCC. In our study, we could not find any significant difference in the VHL or HIF1A genotype frequency between RCC patients and controls, which may suggest that the VHL and HIF1A polymorphisms are not associated with the onset of RCC. Until now, there have been several reports regarding the association of the HIF1A rs11549465 and rs11549467 polymorphisms with various kinds of cancers, including oral cancer [19] , prostate cancer [13, 25] , breast cancer [16] , bladder cancer [18] , and RCC [17] . Recently, a meta-analysis VHL, tumor suppressor gene von Hippel-Lindau; HIF1A, hypoxia-inducible factor-1a; RCC, renal cell cancer; OR, odds ratio; CI, confidence interval.
original articles Annals of Oncology study has been conducted to investigate the association between the two polymorphisms of HIF1A and risk of cancers, and the results suggested the rs11549465 polymorphism was significantly associated with an increased risk of all cancer types, while the rs11549467 polymorphism was significantly associated with decreased breast cancer risk [15] . As for RCC, our results were consistent with one study that also reported that no significant differences in HIF1A genotype distribution were observed between RCC cases and controls [12] but inconsistent with another study that showed that these two polymorphic variants significantly increased risk for RCC patients, however, in a relatively small study population [17] . The study of Ollerenshaw et al. also showed significant differences in the distribution of rs11549465 genotypes among RCC patients with different Robson stages (I, II, III, and IV), which was not observed by the present study. The allele frequency of rs11549465 in their study differed dramatically from that in the present study (71.6% versus 3.8% for T allele). However, the frequency of rs11549465 T allele in our population was very close to the data from HapMap database (4% for T allele). The discrepancies might arise from ethnic population or other unknown factors involved in cancer development or progression. Besides, the sample size of their study was relatively small. Considering these factors, it is statistically plausible that the association was not replicated by our study. Different from other tumors, RCC, especially clearcell RCC, was characterized by inactivation of VHL, in which enhanced transcription activities of HIF1A variants might be overwhelmed by overaccumulation of HIF-1a induced by inactivation of VHL. Therefore, it was reasonable that HIF1A polymorphisms were not associated with RCC risk. It was proposed that HIF1A polymorphisms may affect the neovascularization within or around tumor tissues, but not the transformation of cells; thus the polymorphisms may have effect on the disease condition, progression, or prognosis rather than the onset of cancer [18] . In support of this view, Tanimoto et al. [14] reported that the presence of the HIF1A variants was associated with larger tumor sizes in head and neck squamous cell carcinoma. In bladder cancer, Nadaoka et al. [18] showed the HIF1A variants had a significant association with poor prognosis of the patients undergoing radical cystectomy. In contrast to these reports, we found an inverse relation between VHL/HIF1A polymorphic variants and RCC progression and prognosis. In our study, a significant association between rs2057482 in the 3# UTR region of HIF1A and less frequent lymph node metastasis was observed, and in combined analysis, we found that individuals carrying more variant alleles of the four polymorphisms were associated with less frequent lymph node metastasis and lower clinical stage. Furthermore, the patients with more polymorphic variants had significantly improved survival than those without, which was further confirmed by a multivariate Cox proportional hazards model. In most cancers, high HIF-1a levels have been associated with poor prognosis [26, 27] , which may explain the observations of HIF1A polymorphic variants associated with poor prognosis in head and neck squamous cell carcinoma [14] , bladder cancer [18] , or oral cancer [19] since it was suggested the variants of rs11549465 and rs11549467 enhanced transactivation capacity of HIF1A [14] . In contrast to these studies, we observed an inverse association, which was supported by several studies. For instance, Lidgren et al. [28] used tissue microarray to analyze HIF-1a expression in 216 RCC patients and suggested that patients with high HIF-1a levels tended to have a better prognosis. Similar observation of the inverse correlation between high HIF-1a expression and favorable clinical course has also been reported in lung cancer [29] . Moreover, inverse correlation between RCC survival and other angiogenic variables such as vessel density [30, 31] , endoglin staining [32] , serum vascular endothelial growth factor (VEGF) levels [33] as well as another HIF-regulated gene (carbonic anhydrase IX) [34] has been observed by several studies. Although the exact mechanism remains unknown, these results indicate that up-regulation of HIF-1a and some of its downstream signals may not be all negative, at least in RCC. Since the four SNPs we selected all locate in potentially functional region, we speculate the combined effect of these polymorphisms leading to improved prognosis may be due to the alteration in the regulation of VHL/HIF pathway and finally the expression level of HIF-1a and its downstream signals. However, further functional study is needed to clarify the function of rs2057482 in HIF1A and rs779805 in VHL. It was suggested that microRNAs could act as posttranscriptional regulators of gene expression by either messenger RNA (mRNA) degradation or translational repression [35] . Given the position of 3# UTR where rs2057482 is located, it is biologically plausible that such a variation at this position may alter HIF1A expression by influencing mRNA stability. Besides, it should be noted, according to the HapMap database, there are two other polymorphisms in VHL (rs779803 in promoter region and rs1642742 in 3# UTR region) in complete linkage disequilibrium with rs779805. These polymorphisms may also individually or jointly influence the expression of VHL through altering the affinity of transcription factor binding to the promoter or mRNA stability, which may further affect the expression level of HIF-1a.
Recently, several studies have reported that VHL alterations may have effects on the prognosis of RCC with inconclusive results [36] [37] [38] [39] ; however, it has been suggested that the most useful role for VHL mutational status may be in combination with other potential biomarkers [40] . Recently, Kawai et al. [5] found VEGF polymorphisms had effects on RCC progression or prognosis. Considering the prominent function of pVHL/ HIF-1a/VEGF pathway in RCC, investigation of the combined effect of favorable or unfavorable SNPs may help to accurately stratify RCC patients into subgroups and predict the clinical course of RCC patients. Furthermore, drugs that modulate the downstream targets of the pVHL/HIF/VEGF pathway, including sunitinib, sorafenib, temsirolimus, and bevacizumab, have proven benefit in treating RCC [40] . If an individual's drug susceptibility could be predicted on the basis of VHL/ HIF1A/VEGF genotype, the efficacy of these agents in RCC could be further enhanced.
In summary, no significant differences in genotype or allele frequencies of VHL and HIF1A gene polymorphisms were observed between RCC case and control subjects and we have concluded this study to be negative with respect to RCC susceptibility; however, our results suggest that these four 
